Diffuse Large B Cell Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
ChiCTR2200062052: Canceled by the investigator. Observational study of tislelizumab combined with zanubrutinib, lenalidomide, obinutuzumab, methotrexate, and temozolomide in the treatment of diffuse large B-cell lymphoma with secondary CNS involvement

Not yet recruiting
4
20
 
None
The First Affiliated Hospital of Fujian Medical University ; The First Affiliated Hospital of Fujian Medical University, Beijing Ronghe Medical Development Foundation
diffuse large B-cell lymphoma with secondary CNS involvement
 
 

Download Options